PureTech Health’s (LSE:PRTC) founded entity, Celea Therapeutics, has enrolled the first patient in SURPASS-IPF, a global Phase 3 clinical trial designed to compare its investigational therapy, deupirfenidone, directly against the approved treatment pirfenidone in patients with idiopathic pulmonary fibrosis (IPF).
The randomized study will follow around 1,100 participants over a 52-week period and is the first industry-sponsored Phase 3 IPF trial to evaluate two active therapies without a placebo arm. Every patient enrolled will receive treatment, with the primary objective of determining whether deupirfenidone offers superior preservation of lung function compared with pirfenidone.
Phase 3 Programme Builds on Earlier Clinical Success
The launch of SURPASS-IPF follows Celea’s recent $180 million financing and marks the next stage in the development of deupirfenidone after encouraging Phase 2b results.
Previous clinical data indicated the investigational therapy may significantly reduce the rate of lung function decline while offering an improved tolerability profile compared with existing antifibrotic treatments. The company believes these characteristics could help address barriers that have limited the adoption of current therapies.
Top-line data from the Phase 3 study are anticipated during the second half of 2029. According to the company, discussions with U.S. regulators suggest that a single successful Phase 3 trial may be sufficient to support a regulatory submission, making SURPASS-IPF an important milestone for both Celea Therapeutics and PureTech.
Financial Position Remains a Key Consideration
Despite continued progress across its clinical pipeline, PureTech’s financial profile remains constrained by ongoing operating losses, negative free cash flow and relatively modest revenue generation.
These challenges are partly balanced by a solid balance sheet, while recent management updates have highlighted advances across the company’s development portfolio, improvements in operating losses and available funding runway.
Nevertheless, execution and future financing requirements remain important factors as the company advances its late-stage clinical programmes. Valuation also continues to be affected by the absence of earnings and dividend support, while technical indicators remain broadly neutral.
About PureTech Health
PureTech Health is a London-listed biotherapeutics company that creates and develops businesses focused on innovative treatments for serious diseases using its hub-and-spoke operating model.
One of its founded entities, Boston-based Celea Therapeutics, is developing therapies for respiratory diseases, including idiopathic pulmonary fibrosis.
Its lead candidate, deupirfenidone (LYT-100), is a next-generation deuterated version of pirfenidone designed to improve both efficacy and tolerability. The therapy has received Orphan Drug Designation in both the United States and the European Union and is currently in Phase 3 development as a potential new treatment option for IPF patients.
Leave a Reply